Valsartan
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-21-R-0107
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents4
The Defense Logistics Agency (DLA) Troop Support has announced a forthcoming solicitation for a national requirements contract to supply Valsartan, a pharmaceutical product used primarily for the treatment of high blood pressure and heart failure. This presolicitation notice, identified under procurement number SPE2D2-21-R-0107, outlines the agency’s intent to establish a reliable, long-term supply source for Valsartan tablets in multiple strengths and packaging configurations. Specifically, the contract will cover Valsartan 40MG tablets in 30-count bottles, as well as 80MG, 160MG, and 320MG tablets in 90-count bottles.
The scope of this procurement is national in scale, aiming to meet the ongoing needs of several federal entities, including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and the Bureau of Prisons. The contract will be structured as a firm-fixed price, requirements-type agreement, featuring a one-year base period with four additional one-year option periods. This arrangement is designed to ensure consistent and uninterrupted access to Valsartan for federal healthcare providers and their patients, leveraging the DLA and VA prime vendor programs for efficient distribution.
This acquisition is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with the corresponding Product Service Code 6505, indicating its focus on pharmaceutical products. The procurement will be conducted as an unrestricted, fully competitive acquisition, allowing all qualified sources to submit proposals. The solicitation will be issued in accordance with FAR Part 12, reflecting the commercial nature of the items being procured, and will adhere to the requirements clause outlined in FAR 52.216-21.
Key objectives of this procurement include establishing a dependable national supply chain for Valsartan, ensuring compliance with all applicable federal regulations, and supporting the healthcare missions of multiple federal agencies. The contract will specify annual usage estimates in the Schedule of Supplies section, which will be provided with the solicitation documents.
Interested contractors are encouraged to monitor the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and the SAM.gov portal for the official release of the solicitation and any subsequent updates. The projected solicitation date is June 2021, though DLA reserves the right to adjust this timeline as necessary. All inquiries regarding this opportunity should be directed to the primary point of contact, Christopher Newman ([email protected], 215-737-2905), or the secondary contact, Denise Taubman ([email protected], 215-737-6877).
This opportunity does not include any set-aside requirements and is open to all capable sources. Contractors should note that the requirements and objectives outlined in this notice are expected to remain consistent throughout the contract lifecycle, ensuring a stable framework for performance and compliance.
For further details and to access solicitation documents once available, interested parties should refer to the official notice at https://sam.gov/opp/f5323307f6de417baafcdb2e59aa50b7/view.